Browsing by Author "Geetha, Mani"

Now showing 1 - 3 of 3

CHARACTERIZATION, ANTIMICROBIAL AND ANTICANCER PROPERTIES OF PALLADIUM NANOPARTICLES BIOSYNTHESIZED ROUTED THROUGH BACILLUS SP
(Springer Link, 2023-04-16) Tharani, Jayakumar; Geetha, Mani; Sangeetha, Dhayalan; Ramya, Sennimalai; Kavithaa, Krishnamoorthy; Chandramohan, Govindasamy; Khalid S, Al-Numair; Mohammed A, Alsaif; Yong Pil, Cheon
Bacterial secondary metabolites are the current focus of investigation as a potential solution to various drug resistance and other problems. Palladium nanoparticles produced by Bacillus sp are considered to be green, eco-friendly, cost-effective, and they also have antibacterial and anticancer capabilities which could be used in pharmaceuticals. Agar well screening has proven that the secondary metabolites of Bacillus sp (TAP 4) have antibacterial properties. Ultraviolet–visible (UV–Vis) spectroscopy was used to determine the synthesis of palladium nanoparticles. Scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FTIR), and X ray diffraction (XRD) were used to examine the morphological appearances, stability, and crystalline structure of palladium nanoparticles from the secondary metabolites of Bacillus sp. Using DCFH-DA, we determined the impact of secondary metabolites of synthesized nanoparticles on ROS levels and mitochondrial membrane potential (MMP) by two-fold serial dilution method. On A549 lung cancer cells, the cytotoxicity of synthesized secondary metabolites mediated palladium nanoparticles was measured using MTT assay to determine their anticancer activities. Our findings indicated that their secondary metabolites have a promising role as a first-line cancer drug. However, further research is required to entirely understand their mode of mechanistic action.
THE CREATION OF SELENIUM NANOPARTICLES DECORATED WITH TROXERUTIN AND THEIR ABILITY TO ADAPT TO THE TUMOUR MICROENVIRONMENT HAVE THERAPEUTIC IMPLICATIONS FOR TRIPLE-NEGATIVE BREAST CANCER
(The Royal Society of Chemistry, 2023) Thiruvenkataswamy, Saranya; Krishnamoorthy, Kavithaa; Manickam, Paulpandi; Sennimalai, Ramya; Sureshbabu, Harysh Winster; Geetha, Mani; Sangeetha, Dhayalan; Vellingiri, Balachandar; Arul, Narayanasamy
Despite advancements in treatment, managing aggressive types of breast cancer, particularly Triple Negative Breast Cancer (TNBC), remains a daunting task. Newer chemotherapeutics enhance the multidrug resistance in cancer cells, making them untreatable. The current research work was framed to develop a novel therapeutic target by utilizing the flavanol, troxerutin (TXN) as a drug of interest to target TNBC. And also, to increase the efficiency of the drug at the target site, a nanocarrier called selenium nanoparticles (SeNPs) has been exploited. Thus, the anticancer efficacy of TXN and Se–TXN against TNBC (in vitro and in vivo) has been compared and analysed in the present study. Se–TXN was synthesized by a precipitation approach and characterized by diverse analytical techniques, which confirmed the successful loading of TXN on the SeNPs. The inhibitory concentration (IC50) of Se–TXN was determined to be 6.5 ± 0.5 μg mL−1 according to the in vitro data. Even at lower concentrations, the existence of apoptotic bodies shows that Se–TXN is effective against TNBC. Additionally, the Se–TXN expression study shows that the activation of the caspase cascade pathway, which results in apoptosis, occurs from the downregulation of anti-apoptotic proteins and genes and the upregulation of pro-apoptotic proteins and genes. And the in vivo investigations like histopathology, hematology and biochemical parameters revealed that the Se–TXN had significantly lowered the tumour volume of treated Balb/C mice without having any significant systemic toxicity when compared to other treatment groups. Altogether, our data suggests the efficacy of Se–TXN nanoconjugates as an effective management therapy for treating TNBC.
THE CREATION OF SELENIUM NANOPARTICLES DECORATED WITH TROXERUTIN AND THEIR ABILITY TO ADAPT TO THE TUMOUR MICROENVIRONMENT HAVE THERAPEUTIC IMPLICATIONS FOR TRIPLE-NEGATIVE BREAST CANCER
(Royal Society of Chemistry, 2023-02-09) Thiruvenkataswamy, Saranya; Krishnamoorthy, Kavithaa; Manickam, Paulpandi; Sennimalai, Ramya; Sureshbabu Harysh, Winster; Geetha, Mani; Sangeetha, Dhayalan; Vellingiri, Balachandar; Arul, Narayanasamy
Despite advancements in treatment, managing aggressive types of breast cancer, particularly Triple Negative Breast Cancer (TNBC), remains a daunting task. Newer chemotherapeutics enhance the multidrug resistance in cancer cells, making them untreatable. The current research work was framed to develop a novel therapeutic target by utilizing the flavanol, troxerutin (TXN) as a drug of interest to target TNBC. And also, to increase the efficiency of the drug at the target site, a nanocarrier called selenium nanoparticles (SeNPs) has been exploited. Thus, the anticancer efficacy of TXN and Se–TXN against TNBC (in vitro and in vivo) has been compared and analysed in the present study. Se–TXN was synthesized by a precipitation approach and characterized by diverse analytical techniques, which confirmed the successful loading of TXN on the SeNPs. The inhibitory concentration (IC50) of Se–TXN was determined to be 6.5 ± 0.5 μg mL−1 according to the in vitro data. Even at lower concentrations, the existence of apoptotic bodies shows that Se–TXN is effective against TNBC. Additionally, the Se–TXN expression study shows that the activation of the caspase cascade pathway, which results in apoptosis, occurs from the downregulation of anti-apoptotic proteins and genes and the upregulation of pro-apoptotic proteins and genes. And the in vivo investigations like histopathology, hematology and biochemical parameters revealed that the Se–TXN had significantly lowered the tumour volume of treated Balb/C mice without having any significant systemic toxicity when compared to other treatment groups. Altogether, our data suggests the efficacy of Se–TXN nanoconjugates as an effective management therapy for treating TNBC